Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mongersen (GED-0301) in Active Crohn's Disease
NCT02596893Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Primary completion
- Jan 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 35
01
Overview
A Phase 3 trial of mongersen in Crohn's disease, sponsored by Celgene Corporation. Started Dec 2015; status: terminated.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02596893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596893.